Member Info for L2analyst

The product has been tried and tested and it works

Well at this low share price, someone will have to make a.deal, current mcap of 10 million including cash, company spent far greater amount on exploration and advancing the project

I'm just wondering maybe some have to sell so they could offset against their profit as we are coming to end of financial year, then they will buy back in april

Just copd revenue is over 1 billion per annum!

We have a massive resource of gold and copper just look at the gold price!

Synairgen's other current activities with COVID-19

Since the outbreak of COVID-19, Synairgen has been approached by, and is in discussion with, a number of other medical, scientific, and Governmental bodies (both in the UK, US and internationally) seeking to investigate novel therapeutics in this area

I honestly don't know how these sellers are making any money here, its best to hold or add I would of thought

SNG001 could prove to have an important role to play in outbreaks such as the current COVID-19 epidemic, particularly in respect of the population at highest risk of being severely affected by this and similar viruses.

 

SNG001 was identified in the WHO's Landscape analysis of therapeutics as at 17 February 2020 as the only Phase 2/Phase 3/Observational therapy delivered by the inhaled route (https://www.who.int/blueprint/priority-diseases/key-action/Table_of_therapeutics_Appendix_17022020.pdf?ua=1).

                

Morning all, according to last rns we should get news soon

Sng in talk with uk,usa and worldwide gov. I rest my case

It's in world health organisation

SNG001 was identified in the WHO's Landscape analysis of therapeutics as at 17 February 2020 as the only Phase 2/Phase 3/Observational therapy delivered by the inhaled route (https://www.who.int/blueprint/priority-diseases/key-action/Table_of_therapeutics_Appendix_17022020.pdf?ua=1).

Should go over 100p soon and still it's cheap,

"There are hundreds of respiratory viruses that can cause exacerbations of COPD. IFN-beta, because it stimulates many different intra and extra cellular antiviral pathways, has been shown to be effective in tests against all of the cold and flu viruses that we have encountered in the trial thus far, namely: rhinovirus; influenza; RSV; coronavirus; and parainfluenza.

"The directors believe that such a product could be very successful with annual revenues exceeding $1 billion, just for COPD, with further potential in other patient groups where these normally benign viruses cause serious illness."

See last rns, they are also in talk with usa and other countries

10 million mcap is ridiculous

The way asking price is rising I think theres a announcement soon, imo

Joint venture is highly likely imo, alot of buys are not showing, specially cfd

"The Company is engaged in advanced discussions with a number of potential Asian strategic partners who recognise the rare opportunity presented by the KSK CoW, commencing with development of the BKM copper project. It is the Company's intent to finalise these partnering discussions as soon as is practically possible.

Going to top of the leader board soon and it will then be on radar of alot of investors